BIAF vs CDNA

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Nov 08, 2026

BIAF

58.4
AI Score
VS
BIAF Wins

CDNA

28.3
AI Score

Investment Advisor Scores

BIAF

58score
Recommendation
HOLD

CDNA

28score
Recommendation
SELL

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric BIAF CDNA Winner
Revenue 3.93M 389.01M CDNA
Net Income -12.27M 132.74M CDNA
Net Margin -312.1% 34.1% CDNA
Operating Income -10.46M 122.53M CDNA
ROE -313.5% 28.4% CDNA
ROA -162.5% 20.7% CDNA
Total Assets 7.55M 641.46M CDNA
Cash 2.55M 250.48M CDNA
Current Ratio 1.51 2.31 CDNA
Free Cash Flow -10.47M 40.36M CDNA

Relative Price Performance (Last 90 Days)

BIAF 1M: -34.3% · 3M: +481.9% CDNA 1M: +23.4% · 3M: +76.1%

Current Technical Phase

BIAF

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 35

RSI (14): 34.9 · Price: $2.34

CDNA

Markup
Hold / add on dips

Price above SMA50, rising 50-day trend (20.6% over 20 days), RSI 58

RSI (14): 57.6 · Price: $79.81

Fundamentals Snapshot

Metric BIAF CDNA
Market Cap — —
Forward P/E -0.3 51.0
Trailing P/E — 34.2
Revenue (TTM) — —
Revenue Growth 0.2% 0.4%
Gross Margin 0.3% 0.7%
Operating Margin -2.2% 0.0%
EPS -109.35 2.37
Dividend Yield — —

Frequently Asked Questions

Based on our detailed analysis, BIAF is currently the stronger investment candidate based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.